arrow_back Back to App

Combating Fentanyl: New Classification and Research Rules

This act aims to tighten control over fentanyl-related substances by classifying them as dangerous drugs. Simultaneously, it introduces facilitations for researchers studying these substances, which may accelerate the development of new treatments and addiction combat methods. These changes are intended to enhance public safety by curbing illegal fentanyl trafficking while supporting legitimate medical research.
Key points
All chemically similar fentanyl substances will be treated as Schedule I controlled substances, simplifying their prosecution and control.
Procedures for researchers studying fentanyl and similar substances have been streamlined to accelerate the development of drugs and therapies.
The possibility of conducting research at multiple sites under a single registration has been introduced, facilitating work for large research institutions.
Ensured continuation of research on substances newly added to the list of dangerous drugs, without immediate work interruption.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_171
Sponsor: Rep. Griffith, H. Morgan [R-VA-9]
Process start date: 2023-01-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

HALT Fentanyl Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_171.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-01-09.

What are the main provisions?

Key points include:

  • All chemically similar fentanyl substances will be treated as Schedule I controlled substances, simplifying their prosecution and control.
  • Procedures for researchers studying fentanyl and similar substances have been streamlined to accelerate the development of drugs and therapies.
  • The possibility of conducting research at multiple sites under a single registration has been introduced, facilitating work for large research institutions.
  • Ensured continuation of research on substances newly added to the list of dangerous drugs, without immediate work interruption.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Griffith, H. Morgan [R-VA-9].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Security Health Courts and Law